References
1. Minard-Colin V, Brugieres L, Reiter A, et al. Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. J Clin Oncol . Sep 20 2015;33(27):2963-74. doi:10.1200/JCO.2014.59.5827
2. Gu X, Zheng R, Xia C, et al. Interactions between life expectancy and the incidence and mortality rates of cancer in China: a population-based cluster analysis. Cancer Commun (Lond) . Jul 3 2018;38(1):44. doi:10.1186/s40880-018-0308-x
3. Marginean CO, Melit LE, Horvath E, Gozar H, Chincesan MI. Non-Hodgkin lymphoma, diagnostic, and prognostic particularities in children - a series of case reports and a review of the literature (CARE compliant).Medicine (Baltimore) . Feb 2018;97(8):e9802. doi:10.1097/MD.0000000000009802
4. Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology Am Soc Hematol Educ Program . Dec 2 2016;2016(1):589-597. doi:10.1182/asheducation-2016.1.589
5. Umerez M, Gutierrez-Camino A, Munoz-Maldonado C, Martin-Guerrero I, Garcia-Orad A. MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy. Pharmgenomics Pers Med . 2017;10:69-78. doi:10.2147/PGPM.S107047
6. He J, Liao XY, Zhu JH, et al. Association of MTHFR C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: evidence from a meta-analysis. Sci Rep . Aug 22 2014;4:6159. doi:10.1038/srep06159
7. Gemmati D, Ongaro A, Tognazzo S, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin’s lymphoma patients: association with toxicity and survival. Haematologica . Apr 2007;92(4):478-85. doi:10.3324/haematol.10587
8. De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer . May 2009;45(8):1333-51. doi:10.1016/j.ejca.2008.12.004
9. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab . Jul 1998;64(3):169-72. doi:10.1006/mgme.1998.2714
10. Mashhadi MA, Miri-Moghaddam E, Arbabi N, et al. C677T and A1298C polymorphisms of methylene tetrahydrofolate reductase in non-Hodgkin lymphoma: southeast Iran. Tumori . Aug 2018;104(4):280-284. doi:10.5301/tj.5000634
11. Skibola CF, Forrest MS, Coppede F, et al. Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood . Oct 1 2004;104(7):2155-62. doi:10.1182/blood-2004-02-0557
12. Suthandiram S, Gan GG, Zain SM, et al. Polymorphisms in methylenetetrahydrofolate reductase gene and risk of non-Hodgkin lymphoma in a multi-ethnic population. J Hum Genet . May 2014;59(5):280-7. doi:10.1038/jhg.2014.19
13. Xie SZ, Liu ZZ, Yu JH, et al. Association between the MTHFR C677T polymorphism and risk of cancer: evidence from 446 case-control studies.Tumour Biol . Nov 2015;36(11):8953-72. doi:10.1007/s13277-015-3648-z
14. Kim HN, Lee IK, Kim YK, et al. Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma.Br J Haematol . Feb 2008;140(3):287-94. doi:10.1111/j.1365-2141.2007.06893.x
15. Lee KM, Lan Q, Kricker A, et al. One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia. Hum Genet . Dec 2007;122(5):525-33. doi:10.1007/s00439-007-0431-2
16. Ojha RP, Gurney JG. Methylenetetrahydrofolate reductase C677T and overall survival in pediatric acute lymphoblastic leukemia: a systematic review. Leuk Lymphoma . Jan 2014;55(1):67-73. doi:10.3109/10428194.2013.792336
17. de Deus DM, de Lima EL, Seabra Silva RM, Leite EP, Cartaxo Muniz MT. Influence of Methylenetetrahydrofolate Reductase C677T, A1298C, and G80A Polymorphisms on the Survival of Pediatric Patients with Acute Lymphoblastic Leukemia. Leuk Res Treatment . 2012;2012:292043. doi:10.1155/2012/292043
18. Karas Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I. 5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL).Leuk Res . Oct 2009;33(10):1344-8. doi:10.1016/j.leukres.2008.12.011
19. Lambrecht L, Sleurs C, Labarque V, Dhooge C, Uyttebroeck A. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients. Pharmacogenomics . 2017;18(8):787-795.
20. Zhu L, Wang F, Hu F, et al. Association between MTHFR polymorphisms and overall survival of colorectal cancer patients in Northeast China.Med Oncol . Mar 2013;30(1):467. doi:10.1007/s12032-013-0467-1
21. Yeh CC, Lai CY, Chang SN, et al. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. Int J Clin Oncol . Jun 2017;22(3):484-493. doi:10.1007/s10147-016-1080-z
22. Liu D, Li X, Li X, et al. CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy. Cancer Chemother Pharmacol . May 2019;83(5):939-949. doi:10.1007/s00280-019-03809-2
23. Ose J, Botma A, Balavarca Y, et al. Pathway analysis of genetic variants in folate-mediated one-carbon metabolism-related genes and survival in a prospectively followed cohort of colorectal cancer patients. Cancer Med . May 29 2018;doi:10.1002/cam4.1407
24. Osian G, Procopciuc L, Vlad L, Iancu C, Mocan T, Mocan L. C677T and A1298C mutations in the MTHFR gene and survival in colorectal cancer.J Gastrointestin Liver Dis . Dec 2009;18(4):455-60.
25. Rosolen A, Perkins SL, Pinkerton CR, et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol . Jun 20 2015;33(18):2112-8. doi:10.1200/JCO.2014.59.7203
26. Sandlund JT, Guillerman RP, Perkins SL, et al. International Pediatric Non-Hodgkin Lymphoma Response Criteria. J Clin Oncol . Jun 20 2015;33(18):2106-11. doi:10.1200/JCO.2014.59.0745
27. D’Angelo V, Ramaglia M, Iannotta A, et al. Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate. Leuk Lymphoma . Dec 2013;54(12):2639-44. doi:10.3109/10428194.2013.784758
28. Gross TG, Termuhlen AM. Pediatric non-Hodgkin’s lymphoma. Curr Oncol Rep . Nov 2007;9(6):459-65. doi:10.1007/s11912-007-0064-6
29. Choeyprasert W, Anurathapan U, Pakakasama S, et al. Pediatric non-Hodgkin lymphoma: Characteristics, stratification, and treatment at a single institute in Thailand. Pediatr Int . Jan 2019;61(1):49-57. doi:10.1111/ped.13739
30. Suh JK, Gao YJ, Tang JY, et al. Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia. Cancer Res Treat . Apr 2020;52(2):359-368. doi:10.4143/crt.2019.219
31. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood . Feb 1 2005;105(3):948-58. doi:10.1182/blood-2004-03-0973
32. Muller J, Csoka M, Jakab Z, Ponyi A, Erlaky H, Kovacs G. Treatment of pediatric non-Hodgkin lymphoma in Hungary: 15 years experience with NHL-BFM 90 and 95 protocols. Pediatr Blood Cancer . Mar 2008;50(3):633-5. doi:10.1002/pbc.21144
33. Burkhardt B, Oschlies I, Klapper W, et al. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia . Jan 2011;25(1):153-60. doi:10.1038/leu.2010.245
34. Shimasaki N, Mori T, Samejima H, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol . Feb 2006;28(2):64-8. doi:10.1097/01.mph.0000198269.61948.90
35. Shimasaki N, Mori T, Torii C, et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol . May 2008;30(5):347-52. doi:10.1097/MPH.0b013e318165b25d
36. Seidemann K, Book M, Zimmermann M, et al. MTHFR 677 (C–>T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. Ann Hematol . May 2006;85(5):291-300. doi:10.1007/s00277-005-0072-2
37. Pandith AA, Qasim I, Zahoor W, Shah P, Bhat AR. ACE I/D sequence variants but not MTHFR C677T, is strongly linked to malignant glioma risk and its variant DD genotype may act as a promising predictive biomarker for overall survival of glioma patients. Gene . Jan 10 2018;639:62-68. doi:10.1016/j.gene.2017.10.013
38. Shrubsole MJ, Shu XO, Ruan ZX, et al. MTHFR genotypes and breast cancer survival after surgery and chemotherapy: a report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat . May 2005;91(1):73-9. doi:10.1007/s10549-004-7265-6
39. Lambrecht L, Sleurs C, Labarque V, et al. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients. Pharmacogenomics . Jun 2017;18(8):787-795. doi:10.2217/pgs-2017-0013
40. Xie L, Guo W, Yang Y, Ji T, Xu J. More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate. Oncotarget . Feb 20 2018;9(14):11465-11476. doi:10.18632/oncotarget.23222
41. Visani G, Loscocco F, Ruzzo A, et al. MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. Pharmacogenomics J . May 22 2018;18(3):444-449. doi:10.1038/tpj.2017.48
42. Zetterberg H, Rymo L, Coppola A, D’Angelo A, Spandidos DA, Blennow K. Reply to ‘MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis’. European Journal of Human Genetics . 2002/10/01 2002;10(10):579-582. doi:10.1038/sj.ejhg.5200863
43. Sandlund JT. Non-Hodgkin Lymphoma in Children. Curr Hematol Malig Rep . Sep 2015;10(3):237-243. doi:10.1007/s11899-015-0277-y